Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000905718-13-000180
Filing Date
2013-07-22
Accepted
2013-07-22 10:11:07
Documents
1
Group Members
ABINGWORTH BIOEQUITIES MASTER FUND LTDABINGWORTH BIOVENTURES V CO-INVEST GROWTH EQUITY FUND LPABINGWORTH BIOVENTURES V L.P.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO.10 amarsc13dam10.htm SC 13D/A 180730
  Complete submission text file 0000905718-13-000180.txt   182624
Mailing Address FIRST FLOOR, BLOCK 3, THE OVAL, SHELBOURNE ROAD, BALLSBRIDGE DUBLIN L2 00000
Business Address FIRST FLOOR, BLOCK 3, THE OVAL, SHELBOURNE ROAD, BALLSBRIDGE DUBLIN L2 00000 353 1 6699 020
AMARIN CORP PLC\UK (Subject) CIK: 0000897448 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-52399 | Film No.: 13978478
SIC: 2834 Pharmaceutical Preparations

Mailing Address 38 JERMYN STREET LONDON X0 SW1Y 6DN
Business Address 38 JERMYN STREET LONDON X0 SW1Y 6DN 44 (0)20 7534 1500
Abingworth LLP (Filed by) CIK: 0001397144 (see all company filings)

EIN.: 980518585 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SC 13D/A